CClinicalTrials.gg
CompletedNCT04480216MAGUSUpdated Dec 8, 2021

MAgnetic Gastrointestinal Universal Septotome: a Safety and Feasibility Study (MAGUS)

An interventional study of MAGUS in Diverticulum, Esophageal and Post Gastric Surgery Syndrome, sponsored by Erasme University Hospital. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-08.

Sponsored by Erasme University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A novel magnetic device, called MAgnetic Gastrointestinal Universal Septotome (MAGUS) was designed to improve the Treatment of diverticulum of the esophagus, Pseudo-diverticulum of the upper GI tract, Candy cane syndrome This study aims to evaluating the safety of the feasability of this new device.

Read the detailed description

In this study, the investigators aim at treating different pathological conditions, resulting in the appearance of a septum separating a healthy pathway and a pathological pouch. Food then stagnate in this pouch and results in different symptoms including dysphagia, pain and/or regurgitation or postprandial dysrhythmia.

Esophageal diverticula consists in the apparition of a pouch (diverticulum) alongside the esophagus. Some post-surgical conditions can result in the appearance of pseudo-diverticulum or afferent limb that transforms into a large pouch. One example is the candy cane syndrome, being an afferent loop syndrome post gastrectomy or post Roux-en-Y Gastric Bypass, were the afferent limb becomes a structure similar to a large diverticulum.

All those pathological conditions could be solved by the marsupialization of those (pseudo-)diverticulum. For several years, Zenker's diverticula (pharyngo-esophageal diverticulum) have been treated endoscopically using this technique, providing good clinical results. However, it is difficult to go further than the pharynx with this technique, since it needs specific semi-rigid tools and a stable cutting position. Hence, for further septa of the GI tract, the classic treatment is thoracoscopy and thoracotomy or laparoscopy and laparotomy, depending on the site. Those highly invasive procedures have a significant mortality and morbidity rate respectively of more than 5% and 20% and are liked to different complications including abdominal pain, port site wound infections, intraabdominal collection or anastomosis ulcer.

The MAGUS device consists of a flexible catheter preloaded with a magnetic device, made of two magnets linked by a wire. Each magnet is attached to the catheter and can be dropped separately from this catheter. The magnetic device aims to create an anastomosis by means of compression, using magnetic force and a retractable wire pulling system. For a given septum, the magnets are placed on either sides of the bottom of it. The retractable wire goes then from one another, passing on top of the septum. Both creates compression necrosis. This process induces eventually a cutting of the septum.

Once the cutting is performed, the magnets migrate and are expelled through natural ways.

The MAGUS device is an endoscopic procedure. Above standard of care monitoring, safety assessment of the procedure and device performance decreases the risk and unforeseen events.

02

Conditions studied

  • Diverticulum, Esophageal
  • Post Gastric Surgery Syndrome

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 years or older.
  • Patient has got evaluable symptoms (dysphagia, regurgitation, pain, weight loss, halitosis or others) associated with one of the following pathology:

    1. Diverticulum of the esophagus;
    2. A pseudo-diverticulum of the upper GI tract;
    3. Candy cane syndrome;
  • Willing and able to comply with the study procedures and provide written informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Refractory stenosis of the UGI proximal to the septum;
  • Septum height smaller than 2,5 cm or higher than 6 cm (check through CT scan, Barium Swallow or other imaging method);
  • Coagulation disorders;
  • Previous implantation of a magnetic-sensitive medical device (including active electronic implant, metallic stent, ...);
  • Dysphagia related to motility disorder;
  • Planned MRI in the following month (30 days) of intervention.
  • Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety;
  • Patient went through a surgery less than 8 weeks before implantation of the magnets;
  • Currently enrolled in another clinical trial.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Interventions

  • DeviceMAGUS

    An upper endoscopy will be performed with the use of fluoroscopy. The MAGUS will be placed under fluoroscopy. The good positioning and the absence of any complications will be confirmed by gastroscopy. An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened. The patient will be kept overnight, with liquid food for 2 and mashed food up to 7 days post procedure

05

What researchers measure

Primary outcomes

  1. Technical magnet placement success

    ability to deploy the MAGUS in satisfactory position across the septum (YES/NO)

    Time frame: Day 0

  2. Type of evacuation of the device

    natural or endoscopic

    Time frame: During 28 Days post-placement

  3. Incidence of all adverse event

    SAE during device placement

    Time frame: During 30 days post-placement

Secondary outcomes

  1. Number and type of AE after placement

    Time frame: During 3 month post placement

  2. Patient's report of pain: visual analog scale

    scored by a visual analog scale from 0 to 10 (0=no pain)

    Time frame: Before treatment - Day 1 - Day 14 - Day 28 - Month 3

  3. Number of unplanified interventions

    Time frame: During 3 months post-placement

  4. Change of Eckardt and dysphagia score or GERD HRQL score

    Time frame: Before treatment - Day 1 - Day 14 - Day 28 - Month 3

  5. Patient's satisfaction with the therapy: visual analogue scale

    scored by a visual analogue scale from 0 to 10 (10= fully satisfied)

    Time frame: Day 14 - Day 28 - Month 3

  6. Emptying rate of the diverticular structure

    Time frame: Month 3

  7. Difference of height of the septum cut before and after the treatment

    Time frame: Month 3

  8. Change of SF12 quality of life score

    Time frame: Before treatment - Month 3

06

Study locations

1 site
  • Hopital Erasme
    Bruxelles, 1070, Belgium
07

References and documents

Publications

  • Rio-Tinto R, Huberland F, Van Ouytsel P, Delattre C, Dugardeyn S, Cauche N, Delchambre A, Deviere J, Blero D. Magnet and wire remodeling for the treatment of candy cane syndrome: first case series of a new approach (with video). Gastrointest Endosc. 2022 Jun;95(6):1247-1253. doi: 10.1016/j.gie.2021.12.027. Epub 2022 Jan 1. PubMed 34979115 ↗
  • Huberland F, Rio-Tinto R, Cauche N, Dugardeyn S, Delattre C, Sandersen C, Rocq L, van Ouytsel P, Delchambre A, Deviere J, Blero D. Magnets and a self-retractable wire for endoscopic septotomies: from concept to first-in-human use. Endoscopy. 2022 Jun;54(6):574-579. doi: 10.1055/a-1554-0976. Epub 2021 Oct 29. PubMed 34282579 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT04480216
Lead sponsor
Erasme University Hospital
Responsible party
Sponsor
First posted
Jul 21, 2020
Start date
Feb 19, 2020
Primary completion
Sep 15, 2021
Completion
Sep 15, 2021
Last update
Dec 8, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion